2024-2025 RSV Program Resources

General Resources

Product Monographs

Webinar Recordings

Adverse Effects Following Immunization (AEFI)

Unlike vaccines, mAb are not reportable under the Health Protection and Promotion Act. Adverse Events Following Immunization (AEFI) experienced with Beyfortus should be managed as per your organizational policies and reported to Health Canada using their Side Effect Reporting Form

Letters from CMOH




List of links present in page
  1. https://www.wechu.org/vaccine-providers/2024-2025-rsv-program-resources
  2. https://www.ontario.ca/page/respiratory-syncytial-virus-rsv-prevention-programs#:%7E:text=Through%20the%20RSV%20Prophylaxis%20for,at%20high%20risk%20for%20RSV
  3. https://www.ontario.ca/page/respiratory-syncytial-virus
  4. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.htm
  5. https://ca.gsk.com/en-ca/products/arexvy/
  6. https://www.pfizer.ca/en/our-products/abrysvo-respiratory-syncytial-virus-stabilized-prefusion-f-dubunit-vaccine
  7. https://www.sanofi.com/en/canada/products/vaccines-products/beyfortus
  8. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/consumer-side-effect-reporting-form.html
  9. https://www.wechu.org/sites/default/files/IMMS%20-%20Correspondence%20-%202025.04.04-Infant%20RSV%20CMOH%20letter%20to%20Health%20Care%20Providers%20%284%7B2%7D10%7B2%7D2025%29%20%28ID%20293300%29.pdf
  10. https://www.wechu.org/sites/default/files/IMMS%20-%20Correspondence%20-%202025.04.02-Infant%20RSV%20CMOH%20letter%20to%20Health%20Care%20Providers_Final_FR%20%284%7B2%7D10%7B2%7D20%20%28ID%20293299%29.pdf
  11. https://www.wechu.org/sites/default/files/RSV_CMOH_letter_to_Health_Care_Providers_-_EN_-_2024-08-14.pdf
  12. https://www.wechu.org/sites/default/files/RSV_CMOH_letter_to_MLTC_-_EN_-_2024-08-14.pdf
  13. https://www.wechu.org/sites/default/files/RSV_CMOH_letter_to_RHs_-_EN_-_2024-08-14.pdf
  14. https://www.wechu.org/sites/default/files/2024.08.27-CMOH_Letter__Infant_RSV_Implementation_Health_Care_Providers_EN_0.pdf
  15. https://www.wechu.org/sites/default/files/EN_Infant%20RSV%20Guidance%20for%20Health%20Care%20Providers%20-%20Abrysvo_Version_1.1.pdf
  16. https://www.wechu.org/sites/default/files/EN_Infant%20RSV%20Guidance%20for%20Health%20Care%20Providers%20-Beyfortus_Version_1.1.pdf
  17. https://www.wechu.org/sites/default/files/Older_Adult_High-Risk_RSV_-_Fact_Sheet_V4.0_-_Health_Care_Providers_-_EN_-_2024-08-14.pdf
  18. https://www.wechu.org/sites/default/files/Older_Adult_High-Risk_RSV_-_Fact_Sheet_V4.0_-_Vaccine_Recipients_-_EN_-_2024-08-14.pdf
  19. https://www.wechu.org/sites/default/files/EN_RSV_Fact_Sheet_0.pdf
  20. https://www.wechu.org/sites/default/files/EN_Immunity_Fact_Sheet_0.pdf
  21. https://www.wechu.org/sites/default/files/EN_Beyfortus_Fact_Sheet_0.pdf
  22. https://www.wechu.org/sites/default/files/EN_Abrysvo_in_Pregnancy_Fact_Sheet_0.pdf
  23. https://www.wechu.org/tags/adult-vaccines
  24. https://www.wechu.org/tags/health-care-providers